Jascayd® is the commercial brand name of Nerandomilast Tablets, an orally active selective phosphodiesterase 4 (PDE4) inhibitor. It exerts anti-inflammatory effects by increasing intracellular cyclic adenosine monophosphate (cAMP) levels, thereby modulating inflammatory cell function. Main IndicationsTreatment of moderate to severe…
Xiangerkang® is the Chinese commercial brand name of Methyldopa Tablets, an orally active centrally acting antihypertensive agent. It acts as a false neurotransmitter precursor, stimulating central α₂-adrenergic receptors to reduce sympathetic outflow, thereby lowering blood pressure. Main IndicationsTreatment of hypertension,…
Orpathys® is the commercial brand name of Savolitinib Tablets, an orally selective c-Met inhibitor developed by Hutchison MediPharma and AstraZeneca. It blocks the c-Met/HGF signaling pathway, inhibiting tumor cell proliferation, invasion, and angiogenesis driven by c-Met aberrations. Main IndicationsTreatment of…
GaoruiZhe® is the commercial brand name of Golidocitinib Capsules, an orally active JAK1 inhibitor developed by Dizal. It selectively inhibits Janus kinase 1 (JAK1), blocking JAK-STAT signaling pathways to suppress tumor cell proliferation and survival. Main IndicationsTreatment of adult patients…
OPDIVO® is the commercial brand name of Nivolumab Injection, a fully human anti-PD-1 monoclonal antibody developed by Bristol Myers Squibb. It blocks the binding of PD-1 receptor to its ligands PD-L1 and PD-L2, restoring the anti-tumor immune activity of T…
ELUNATE® is the commercial brand name of Fruquintinib Capsules, an orally active VEGFR tyrosine kinase inhibitor developed by Hutchison MediPharma and licensed to Eli Lilly. It selectively inhibits vascular endothelial growth factor receptors (VEGFR1, 2, 3), blocking tumor angiogenesis and…
Enruining® is the commercial brand name of Dexrazoxane for Injection, a cardioprotective agent developed by Gland Pharma Limited. It acts as a free radical scavenger and iron chelator, reducing anthracycline-induced cardiac toxicity by preventing the formation of iron-doxorubicin complexes that…
Imbruvica® is the commercial brand name of Ibrutinib Capsules, an orally active Bruton’s tyrosine kinase (BTK) inhibitor developed by Pharmacyclics. It covalently binds to BTK, blocking B-cell receptor signaling pathways to inhibit B-cell proliferation and survival. Main IndicationsTreatment of chronic…
TAGRISSO® is the commercial brand name of Osimertinib Mesylate Tablets, an orally active third-generation EGFR tyrosine kinase inhibitor developed by AstraZeneca. It selectively inhibits EGFR activating mutations and the T790M resistance mutation, blocking downstream signaling pathways to suppress tumor cell…
Zavesca® is the commercial brand name of Miglustat Capsules, an orally active glucosylceramide synthase inhibitor developed by Janssen. It reduces the synthesis of glycosphingolipids, thereby decreasing the accumulation of toxic substrates in lysosomes. Main IndicationsTreatment of mild to moderate type…